Experience

Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Five Prime Therapeutics, Inc. of its common stock for up to an aggregate amount of $75 million. Five…

Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Atreca, Inc. of its common stock for up to an aggregate amount of $100 million. Atreca is a…

Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Turning Point Therapeutics, Inc. of its common stock for up to an aggregate amount of $250 million…

Davis Polk advised the representatives of the several underwriters in connection with the $703.5 million initial public offering of 33,500,000 shares of common stock of Rackspace Technology…

Davis Polk advised the underwriters in connection with an initial public offering of 11,000,000 shares of common stock of Nurix Therapeutics, Inc. at $19 per share, for total gross proceeds…

Davis Polk advised the representatives of the several underwriters in connection with a $125 million SEC-registered common stock offering by Atreca, Inc. The common stock is listed on…

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Zscaler, Inc. of $1.15 billion aggregate principal amount of its 0.125%…

Davis Polk advised Equinix, Inc. on an SEC-registered offering of $2.6 billion aggregate principal amount of senior notes. The offering consisted of $500 million aggregate principal amount…

Davis Polk advised the initial purchasers on a Rule 144A offering by Jazz Investments I Limited, a wholly owned subsidiary of Jazz Pharmaceuticals plc, of $850 million aggregate…

Davis Polk advised the joint book-running managers in connection with a $325 million SEC-registered common stock offering by Turning Point Therapeutics, Inc. The common stock is listed…